Validity of Biomarkers of Early Circulatory Impairment to Predict Outcome: A Retrospective Analysis

Objectives: The definition of circulatory impairment in the premature infant is controversial. Current research suggests overdiagnosis and overtreatment. We aimed to analyse which biomarkers move clinicians to initiate cardiovascular treatment (CVT). The prognostic capacity for adverse outcome (deat...

Full description

Bibliographic Details
Main Authors: María Carmen Bravo, Paloma López-Ortego, Laura Sánchez, Rosario Madero, Fernando Cabañas, Armin Koch, Héctor Rojas-Anaya, Heike Rabe, Adelina Pellicer
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-05-01
Series:Frontiers in Pediatrics
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fped.2019.00212/full
id doaj-c251d5e029aa44c5a7ee1f1d9daa1fd6
record_format Article
spelling doaj-c251d5e029aa44c5a7ee1f1d9daa1fd62020-11-25T01:32:14ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602019-05-01710.3389/fped.2019.00212440664Validity of Biomarkers of Early Circulatory Impairment to Predict Outcome: A Retrospective AnalysisMaría Carmen Bravo0Paloma López-Ortego1Laura Sánchez2Rosario Madero3Fernando Cabañas4Fernando Cabañas5Armin Koch6Héctor Rojas-Anaya7Heike Rabe8Adelina Pellicer9Department of Neonatology, La Paz University Hospital, Madrid, SpainDepartment of Neonatology, La Paz University Hospital, Madrid, SpainDepartment of Neonatology, La Paz University Hospital, Madrid, SpainDivision of Statistics, La Paz University Hospital, Madrid, SpainDepartment of Neonatology, La Paz University Hospital, Madrid, SpainDepartment of Pediatrics and Neonatology, Quironsalud Madrid University Hospital, Madrid, SpainMedizinische Hochschule Hannover, Institut für Biometrie, Hannover, GermanyAcademic Department of Paediatrics, Brighton and Sussex Medical School, Brighton, United KingdomAcademic Department of Paediatrics, Brighton and Sussex Medical School, Brighton, United KingdomDepartment of Neonatology, La Paz University Hospital, Madrid, SpainObjectives: The definition of circulatory impairment in the premature infant is controversial. Current research suggests overdiagnosis and overtreatment. We aimed to analyse which biomarkers move clinicians to initiate cardiovascular treatment (CVT). The prognostic capacity for adverse outcome (death and/or moderate-severe brain damage by cranial ultrasound at term equivalent) of these biomarkers was evaluated.Study Design: Retrospective data analysis from preterm infants enrolled in a placebo-controlled trial on dobutamine for low superior vena cava (SVC) flow, who showed normal SVC flow within the first 24 h (not randomized). Five positive biomarkers were considered: MABP < gestational age (GA)-1 mmHg; MABP < GA-5 mmHg; lactate > 4 mmol/L; BE < −9 mmol/L; SVC flow <51 ml/kg/min.Results:Ninety eight infants formed the study cohort. Thirty six received CVT (2–95 h). Logistic regression models adjusted for gestational age showed a positive association between CVT and the risk of death or moderate-severe abnormal cranial ultrasound at term equivalent [(OR 5.2, 95%CI: 1.8–15.1) p = 0.002]. MABP < GA-1 mmHg and lactate > 4 mmol/L were the most prevalent biomarkers at start of treatment. Low BE, high serum lactate and low SVC flow at first echocardiography showed a trend toward being associated with adverse outcome, although not statistically significant.Conclusions: Low blood pressure and high lactate are the most prevalent biomarkers used for CVT prescription. Lactic acidosis and low SVC flow early after birth showed a trend toward being associated with adverse outcome. These findings support using a combination of biomarkers for inclusion in a placebo-controlled trial on CVT during transitional circulation.https://www.frontiersin.org/article/10.3389/fped.2019.00212/fulltransitional circulationcirculatory impairmentcardiovascular treatmenthypotensionpreterm
collection DOAJ
language English
format Article
sources DOAJ
author María Carmen Bravo
Paloma López-Ortego
Laura Sánchez
Rosario Madero
Fernando Cabañas
Fernando Cabañas
Armin Koch
Héctor Rojas-Anaya
Heike Rabe
Adelina Pellicer
spellingShingle María Carmen Bravo
Paloma López-Ortego
Laura Sánchez
Rosario Madero
Fernando Cabañas
Fernando Cabañas
Armin Koch
Héctor Rojas-Anaya
Heike Rabe
Adelina Pellicer
Validity of Biomarkers of Early Circulatory Impairment to Predict Outcome: A Retrospective Analysis
Frontiers in Pediatrics
transitional circulation
circulatory impairment
cardiovascular treatment
hypotension
preterm
author_facet María Carmen Bravo
Paloma López-Ortego
Laura Sánchez
Rosario Madero
Fernando Cabañas
Fernando Cabañas
Armin Koch
Héctor Rojas-Anaya
Heike Rabe
Adelina Pellicer
author_sort María Carmen Bravo
title Validity of Biomarkers of Early Circulatory Impairment to Predict Outcome: A Retrospective Analysis
title_short Validity of Biomarkers of Early Circulatory Impairment to Predict Outcome: A Retrospective Analysis
title_full Validity of Biomarkers of Early Circulatory Impairment to Predict Outcome: A Retrospective Analysis
title_fullStr Validity of Biomarkers of Early Circulatory Impairment to Predict Outcome: A Retrospective Analysis
title_full_unstemmed Validity of Biomarkers of Early Circulatory Impairment to Predict Outcome: A Retrospective Analysis
title_sort validity of biomarkers of early circulatory impairment to predict outcome: a retrospective analysis
publisher Frontiers Media S.A.
series Frontiers in Pediatrics
issn 2296-2360
publishDate 2019-05-01
description Objectives: The definition of circulatory impairment in the premature infant is controversial. Current research suggests overdiagnosis and overtreatment. We aimed to analyse which biomarkers move clinicians to initiate cardiovascular treatment (CVT). The prognostic capacity for adverse outcome (death and/or moderate-severe brain damage by cranial ultrasound at term equivalent) of these biomarkers was evaluated.Study Design: Retrospective data analysis from preterm infants enrolled in a placebo-controlled trial on dobutamine for low superior vena cava (SVC) flow, who showed normal SVC flow within the first 24 h (not randomized). Five positive biomarkers were considered: MABP < gestational age (GA)-1 mmHg; MABP < GA-5 mmHg; lactate > 4 mmol/L; BE < −9 mmol/L; SVC flow <51 ml/kg/min.Results:Ninety eight infants formed the study cohort. Thirty six received CVT (2–95 h). Logistic regression models adjusted for gestational age showed a positive association between CVT and the risk of death or moderate-severe abnormal cranial ultrasound at term equivalent [(OR 5.2, 95%CI: 1.8–15.1) p = 0.002]. MABP < GA-1 mmHg and lactate > 4 mmol/L were the most prevalent biomarkers at start of treatment. Low BE, high serum lactate and low SVC flow at first echocardiography showed a trend toward being associated with adverse outcome, although not statistically significant.Conclusions: Low blood pressure and high lactate are the most prevalent biomarkers used for CVT prescription. Lactic acidosis and low SVC flow early after birth showed a trend toward being associated with adverse outcome. These findings support using a combination of biomarkers for inclusion in a placebo-controlled trial on CVT during transitional circulation.
topic transitional circulation
circulatory impairment
cardiovascular treatment
hypotension
preterm
url https://www.frontiersin.org/article/10.3389/fped.2019.00212/full
work_keys_str_mv AT mariacarmenbravo validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis
AT palomalopezortego validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis
AT laurasanchez validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis
AT rosariomadero validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis
AT fernandocabanas validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis
AT fernandocabanas validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis
AT arminkoch validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis
AT hectorrojasanaya validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis
AT heikerabe validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis
AT adelinapellicer validityofbiomarkersofearlycirculatoryimpairmenttopredictoutcomearetrospectiveanalysis
_version_ 1725082433808760832